Arialys Therapeutics

📍 La Jolla, United States👥 19 employees💰 Last funded May 2023
Pharmaceutical Manufacturing
LinkedIn
We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Arialys Therapeutics?
Arialys Therapeutics has 1 investors on record on gritt.io.
When did Arialys Therapeutics last raise funding?
The most recent investment in Arialys Therapeutics recorded on gritt.io was in May 2023.
What industry is Arialys Therapeutics in?
Arialys Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Arialys Therapeutics based?
Arialys Therapeutics is headquartered in La Jolla, United States.